Viibryd Vilazodone Withdrawal

If you want to taper off the Viibryd and you are not sure where to start, you can click here and read the bestselling book, How to Get Off Psychoactive Drugs Safely or send Jim Harper an email at and he will guide you through the process of Viibryd withdrawal.

Viibryd ( Vilazodone ) Withdrawal

If you are experiencing brain zaps, electrical jolts in the head, click here

Understanding Viibryd (Vilazodone) Withdrawal: Symptoms, Management, and Recovery

Viibryd, known generically as vilazodone, is a medication primarily used to treat major depressive disorder (MDD). As an antidepressant, it combines the properties of a selective serotonin reuptake inhibitor (SSRI) and a serotonin receptor agonist, offering a unique mechanism of action that sets it apart from other antidepressants. Despite its effectiveness in managing depression, discontinuing Viibryd can lead to withdrawal symptoms. This article delves into the nature of Viibryd withdrawal, its symptoms, management strategies, and the path to recovery.

Understanding Viibryd and Its Mechanism

What is Viibryd?

Viibryd (vilazodone hydrochloride) is an FDA-approved medication for the treatment of major depressive disorder. It was first approved in 2011 and is known for its dual mechanism as an SSRI and a partial agonist of the serotonin 1A receptor. This dual action is thought to contribute to its antidepressant effects, potentially offering benefits over traditional SSRIs by providing more immediate relief of depressive symptoms and potentially fewer sexual side effects.

How Viibryd Works

Viibryd increases serotonin levels in the brain by inhibiting its reuptake into neurons (a common mechanism shared with other SSRIs). Additionally, as a partial agonist at the serotonin 1A receptor, it helps modulate serotonin activity more precisely. This dual mechanism aims to improve mood and anxiety symptoms more effectively.

The Challenge of Discontinuation

Why Withdrawal Happens

Withdrawal symptoms occur when the body and brain have adapted to the presence of a medication, and then that medication is abruptly reduced or stopped. With Viibryd, the brain becomes accustomed to the elevated levels of serotonin. When the medication is discontinued, especially suddenly, the brain needs time to readjust to the lower levels of serotonin, leading to withdrawal symptoms.

Common Withdrawal Symptoms

Withdrawal from Viibryd can result in a range of symptoms, which can vary in intensity and duration. Common symptoms include:
• Flu-like symptoms: Fatigue, muscle aches, and headaches.
• Gastrointestinal issues: Nausea, vomiting, and diarrhea.
• Sensory disturbances: Known as "brain zaps" (electric shock-like sensations in the brain), dizziness, and blurred vision.
• Sleep disturbances: Insomnia, vivid dreams, and nightmares.
• Emotional changes: Anxiety, irritability, mood swings, and depression.
• Cognitive symptoms: Difficulty concentrating, confusion, and memory problems.

These symptoms are typically temporary but can be distressing and disruptive.

Managing Viibryd Withdrawal

Gradual Tapering

One of the most effective ways to minimize withdrawal symptoms is through a gradual tapering process. This involves slowly reducing the dosage of Viibryd under the guidance of a healthcare provider. A typical tapering schedule might reduce the dosage by 10-25% every 1-2 weeks, though this can vary depending on the individual’s response and the initial dose.

Medical Supervision

It is crucial to undergo the tapering process under the supervision of a healthcare professional. They can provide personalized guidance, adjust the tapering schedule as needed, and offer support for managing symptoms. In some cases, switching to a different SSRI with a longer half-life before discontinuing entirely might be recommended to ease the transition and reduce withdrawal effects. This is not recommended.

Symptomatic Treatment

Managing specific withdrawal symptoms can make the process more bearable. Some strategies include:
• Over-the-counter medications: Pain relievers like acetaminophen or ibuprofen can help with headaches and muscle aches.
• Hydration and diet: Staying hydrated and maintaining a balanced diet can support overall health and alleviate some gastrointestinal symptoms.
• Sleep hygiene: Practices like maintaining a regular sleep schedule, avoiding caffeine before bedtime, and creating a restful environment can improve sleep disturbances.
• Stress management techniques: Practices such as mindfulness, meditation, yoga, and deep breathing exercises can help manage anxiety and mood swings.

Support Systems

Having a strong support system can significantly aid in managing withdrawal. Friends, family, and support groups can provide emotional support and practical assistance during the withdrawal period.

Alternative Therapies

Some individuals find relief in alternative therapies such as acupuncture, massage therapy, and herbal supplements. However, it's essential to consult with a healthcare provider before starting any alternative treatment to ensure safety and compatibility with the withdrawal process.

Long-term Recovery

Understanding Post-Acute Withdrawal Syndrome (PAWS)
While acute withdrawal symptoms typically resolve within a few weeks, some individuals may experience lingering symptoms, a condition known as Post-Acute Withdrawal Syndrome (PAWS). Symptoms of PAWS can include prolonged mood disturbances, anxiety, and cognitive difficulties. These symptoms can persist for months but generally decrease in intensity over time.

Psychological Support

Engaging in psychotherapy can be beneficial during and after withdrawal. Cognitive-behavioral therapy (CBT), in particular, is effective in addressing the psychological aspects of withdrawal and developing coping strategies for managing symptoms and preventing relapse.

Lifestyle Adjustments

Adopting a healthy lifestyle can support long-term recovery. Regular physical activity, a nutritious diet, adequate sleep, and stress management techniques can improve overall well-being and resilience against withdrawal symptoms.

Monitoring and Follow-up

Regular follow-up appointments with a healthcare provider are crucial during the withdrawal and recovery period. These visits allow for monitoring of symptoms, adjusting treatment plans as needed, and providing ongoing support.

Resources for Further Reading

1. National Institute of Mental Health (NIMH) - Provides information on depression and treatment options.
2. Mayo Clinic - Offers guidance on managing withdrawal symptoms and tapering off medications.
3. American Psychological Association (APA) - Resources on psychotherapy and mental health support.
4. Support Groups - Organizations like the National Alliance on Mental Illness (NAMI) provide support groups for individuals going through medication withdrawal.

By educating oneself about Viibryd withdrawal and utilizing available resources, individuals can empower themselves to navigate this challenging process successfully.

Comprehensive Guide to Viibryd (Vilazodone Hydrochloride) Side Effects


Viibryd (vilazodone hydrochloride) is a prescription medication primarily used to treat major depressive disorder (MDD). Approved by the FDA in 2011, Viibryd combines the properties of a selective serotonin reuptake inhibitor (SSRI) and a serotonin receptor agonist, offering a unique mechanism of action. While it can be effective in alleviating symptoms of depression, it is also associated with various side effects. This article provides a detailed examination of the potential side effects of Viibryd, including common, less common, and serious adverse effects.

Mechanism of Action

Dual Mechanism

Viibryd's dual mechanism involves the inhibition of serotonin reuptake and partial agonism at the 5-HT1A receptor. By preventing the reuptake of serotonin, Viibryd increases the availability of this neurotransmitter in the brain, which can improve mood and reduce anxiety. The partial agonist activity at the 5-HT1A receptor is believed to enhance these effects and potentially mitigate some of the side effects commonly associated with traditional SSRIs.

Common Side Effects

Gastrointestinal Issues

Gastrointestinal side effects are among the most commonly reported with Viibryd. These include:

• Nausea: Many patients experience nausea, particularly when starting the medication or increasing the dose. Taking Viibryd with food can help mitigate this effect.
• Diarrhea: Diarrhea is another frequent side effect, which can range from mild to severe.
• Vomiting: Some patients report vomiting, especially during the initial phase of treatment.

Nervous System Effects

Viibryd can affect the nervous system in various ways:

• Dizziness: Dizziness is a common side effect, which may occur more frequently upon standing up quickly.
• Headache: Headaches are also commonly reported and can sometimes be severe.
• Insomnia: Difficulty sleeping or maintaining sleep is a frequent issue, potentially exacerbated by the medication’s stimulating effects.

Sexual Dysfunction

While Viibryd is often promoted as having fewer sexual side effects than other SSRIs, some patients still report issues such as:

• Decreased libido: A reduced interest in sexual activity.
• Erectile dysfunction: Difficulty achieving or maintaining an erection.
• Anorgasmia: Difficulty reaching orgasm.

Weight Changes

Weight changes, though not as common as with some other antidepressants, can still occur:

• Weight gain: Some patients may experience an increase in weight.
• Weight loss: Conversely, a decrease in appetite can lead to weight loss in some individuals.

Less Common Side Effects

Cardiovascular Effects

Viibryd can have effects on the cardiovascular system, though these are less common:

• Palpitations: Some patients report an awareness of their heartbeat, which can be unsettling.
• Increased blood pressure: Although rare, there can be increases in blood pressure.

Dermatological Reactions

Skin-related side effects are infrequent but can occur:
• Rash: Some patients develop a rash, which can vary in severity.
• Pruritus: Itching of the skin without an apparent rash.

Musculoskeletal Effects

These side effects are also less common but noteworthy:

• Muscle spasms: Involuntary muscle contractions can occur.
• Arthralgia: Joint pain is occasionally reported.

Serious Side Effects

Serotonin Syndrome

One of the most serious potential side effects of Viibryd is serotonin syndrome, a condition resulting from excessive accumulation of serotonin. Symptoms of serotonin syndrome can include:

• Confusion: Mental confusion and agitation.
• Fever: High body temperature.
• Sweating: Profuse sweating.
• Tachycardia: Rapid heartbeat.
• Hyperreflexia: Exaggerated reflexes.
• Tremors: Shaking and muscle rigidity.

Serotonin syndrome is a medical emergency and requires immediate attention.

Suicidal Thoughts and Behaviors

Like other antidepressants, Viibryd carries a black box warning about the increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults. Symptoms to watch for include:

• Increased depression: Worsening of depressive symptoms.
• Suicidal ideation: New or increased thoughts of suicide.
• Behavioral changes: Increased aggression, agitation, or unusual behavior.

Severe Allergic Reactions

Severe allergic reactions, while rare, can occur and manifest as:

• Anaphylaxis: A severe, potentially life-threatening allergic reaction involving difficulty breathing, swelling, and hives.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes and lips.


Viibryd can sometimes cause hyponatremia, a condition characterized by low sodium levels in the blood. Symptoms include:

• Headache: Severe or persistent headache.
• Confusion: Mental confusion and lethargy.
• Seizures: In severe cases, seizures may occur.

Bleeding Risk

As with other SSRIs, Viibryd can increase the risk of bleeding, particularly when taken with other medications that affect bleeding, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or anticoagulants. Signs of increased bleeding risk include:

• Bruising easily: Increased tendency to bruise.
• Gastrointestinal bleeding: Blood in stools or vomit.
• Nosebleeds: Frequent nosebleeds.

Risk Factors and Precautions

Individual Risk Factors

Certain factors can increase the likelihood of experiencing side effects from Viibryd:

• Age: Older adults may be more susceptible to side effects due to decreased liver and kidney function.
• Coexisting medical conditions: Conditions such as liver disease, kidney disease, and cardiovascular issues can increase risks.
• Concurrent medications: Interactions with other medications, including other antidepressants, antiplatelet drugs, and anticoagulants, can heighten side effects.
Monitoring and Safety Precautions
Regular monitoring by a healthcare provider is essential for anyone taking Viibryd. This includes:
• Regular check-ups: To monitor for side effects and adjust dosages as needed.
• Blood tests: Periodic blood tests to check for issues like hyponatremia.
• Mental health assessments: Ongoing evaluations to assess for worsening depression or suicidal thoughts.

Managing Side Effects

Gradual Dose Adjustments

One way to manage side effects is through gradual dose adjustments. Starting at a lower dose and slowly increasing it can help the body adapt and reduce the severity of side effects.
Lifestyle Modifications

Certain lifestyle modifications can help mitigate side effects:

• Diet and hydration: Eating a balanced diet and staying hydrated can alleviate gastrointestinal issues.
• Exercise: Regular physical activity can help with weight management and improve mood.
• Sleep hygiene: Maintaining a consistent sleep schedule and creating a restful sleep environment can help with insomnia.

Symptomatic Treatments

For persistent side effects, symptomatic treatments may be necessary:
• Anti-nausea medications: Medications like ondansetron can help manage nausea.
• Pain relievers: Over-the-counter pain medications can help with headaches and muscle pain.
• Sleep aids: Melatonin or other sleep aids, under a doctor's guidance, can help with insomnia.

Switching Medications

If side effects are severe and unmanageable, switching to a different antidepressant may be necessary. This should always be done under the guidance of a healthcare provider to ensure a safe transition.

Patient Experiences and Testimonials

Individual Variability

Patient experiences with Viibryd can vary widely. Some individuals report significant relief from depressive symptoms with minimal side effects, while others may struggle with more severe adverse reactions.

Case Studies
• Case Study 1: A 35-year-old woman experienced significant improvement in her depressive symptoms with Viibryd but struggled with persistent nausea. After several weeks of gradual dose adjustment and dietary changes, her symptoms improved.
• Case Study 2: A 50-year-old man developed severe insomnia and increased anxiety after starting Viibryd. With the help of his healthcare provider, he switched to another antidepressant and his side effects subsided.
• Case Study 3: A 28-year-old woman experienced severe brain zaps and dizziness after abruptly discontinuing Viibryd. Gradual tapering and supportive therapies eventually helped her manage and overcome these withdrawal symptoms.

Viibryd (vilazodone hydrochloride) is an effective treatment for major depressive disorder but is associated with a range of potential side effects. Understanding these side effects, from common and manageable to serious and rare, is crucial for both patients and healthcare providers. Through careful monitoring, gradual dose adjustments, and supportive therapies, many of these side effects can be managed effectively, allowing patients to benefit from the therapeutic effects of Viibryd while minimizing discomfort.

1. Stuivenga M, Giltay EJ, Cools O, Roosens L, Neels H, Sabbe B. Evaluation of vilazodone for the treatment of depressive and anxiety disorders. Expert Opin Pharmacother. 2019 Feb;20(3):251-260. doi: 10.1080/14656566.2018.1549542. Epub 2018 Nov 26. PMID: 30475091. [cited 2022 June 14]

2. Walsh WJ (2012). Nutrient Power. Skyhorse Publishing, New York, NY. Crayton JW, Walsh WJ (2007). J Trace Elements Med Biol.21:17-21.[cited 2022 June 14]

3. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol. 2015;23(1):1-21. doi:10.1037/a0038550 [cited 2022 June 14]

4. Knapen J, Vancampfort D, Moriën Y, Marchal Y. Exercise therapy improves both mental and physical health in patients with major depression. Disabil Rehabil. 2015;37(16):1490-5. doi: 10.3109/09638288.2014.972579. Epub 2014 Oct 24. PMID: 25342564. [cited 2022 June 14]

5. Cuomo A, Maina G, Bolognesi S, Rosso G, Beccarini Crescenzi B, Zanobini F, Goracci A, Facchi E, Favaretto E, Baldini I, Santucci A, Fagiolini A. Prevalence and Correlates of Vitamin D Deficiency in a Sample of 290 Inpatients With Mental Illness. Front Psychiatry. 2019 Mar 29;10:167. doi: 10.3389/fpsyt.2019.00167. PMID: 31001150; PMCID: PMC6455075. [cited 2022 June 14]

6. Rao TS, Asha MR, Ramesh BN, Rao KS. Understanding nutrition, depression and mental illnesses. Indian J Psychiatry. 2008;50(2):77-82. doi:10.4103/0019-5545.42391 [cited 2022 June 14]

7. Briguglio M, Dell’Osso B, Panzica G, et al. Dietary Neurotransmitters: A Narrative Review on Current Knowledge. Nutrients. 2018;10(5):591. Published 2018 May 10. doi:10.3390/nu10050591 [cited 2022 June 14]

8. Pandya CD, Howell KR, Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:214-223. doi:10.1016/j.pnpbp.2012.10.017 [cited 2022 June 14]

9. Osher Y, Belmaker RH. Omega-3 fatty acids in depression: a review of three studies. CNS Neurosci Ther. 2009 Summer;15(2):128-33. doi: 10.1111/j.1755-5949.2008.00061.x. PMID: 19499625; PMCID: PMC6494070. [cited 2022 June 14]

10. Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J. Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance. Phytother Res. 2018 May;32(5):865-891. doi: 10.1002/ptr.6033. Epub 2018 Feb 21. PMID: 29464801; PMCID: PMC5938102. [cited 2022 June 14]

11. Firth J, Gangwisch J, Borsini A, Wootten R, Mayar E, Food and Mood – How do Diet and Nutrition Affect Mental Well-being? BMJ 2020;369:m2382 [cited 2022 June 14]

12. Substance Abuse and Mental Health Services Administration. DSM-5 Changes: Implications for Child Serious Emotional Disturbance [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2016 Jun. Table 9, DSM-IV to DSM-5 Major Depressive Episode/Disorder Comparison. Available from: [cited 2022 June 14]

13. World Health Organization fact sheet, Depression [published online 13 Sept 2021] [cited 2022 June 14]

14. Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice. Prescrire Int. 2011 May;20(116):128-33. PMID: 21648180. [cited 2022 June 14]

15. Nanthakumaran S, Sridharan S, Somagutta MR, Arnold AA, May V, Pagad S, Malik BH. The Gut-Brain Axis and Its Role in Depression. Cureus. 2020 Sep 6;12(9):e10280. doi: 10.7759/cureus.10280. PMID: 33042715; PMCID: PMC7538207. [cited 2022 June 14]

16. Prasko J. Bright light therapy. Neuro Endocrinol Lett. 2008 Nov;29 Suppl 1:33-64. PMID: 19029878. [cited 2022 June 14]

17. Ljungberg, Tina et al. “Evidence of the Importance of Dietary Habits Regarding Depressive Symptoms and Depression.” International journal of environmental research and public health vol. 17,5 1616. 2 Mar. 2020, doi:10.3390/ijerph17051616[cited 2022 June 14]

18. David D, Cristea I, Hofmann SG. Why Cognitive Behavioral Therapy Is the Current Gold Standard of PsychotherapyFront Psychiatry. 2018;9:4. Published 2018 Jan 29. doi:10.3389/fpsyt.2018.00004 [cited 2022 June 14]

19. Zell M, Grundmann O. An orthomolecular approach to the prevention and treatment of psychiatric disorders. Adv Mind Body Med. 2012 Fall;26(2):14-28. PMID: 23341413. [cited 2022 June 14]

20. Mason LH, Harp JP, Han DY. Pb neurotoxicity: neuropsychological effects of lead toxicity. Biomed Res Int. 2014;2014:840547. doi: 10.1155/2014/840547. Epub 2014 Jan 2. PMID: 24516855; PMCID: PMC3909981. [cited 2022 June 14]

21. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT. EDC-2: The Endocrine Society’s Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev. 2015 Dec;36(6):E1-E150. doi: 10.1210/er.2015-1010. Epub 2015 Nov 6. PMID: 26544531; PMCID: PMC4702494. [cited 2022 June 14]

22. Sharma A, Madaan V, Petty FD. Exercise for mental healthPrim Care Companion J Clin Psychiatry. 2006;8(2):106. doi:10.4088/pcc.v08n0208a [cited 2022 June 14]